clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Diphtheria D004165 2 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Dermatomycoses D003881 17 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Cysts D003560 4 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cross Infection D003428 9 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Confusion D003221 4 associated lipids
Colitis D003092 69 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Chlamydia Infections D002690 7 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Bronchitis D001991 6 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Bronchiolitis D001988 6 associated lipids
Bronchiectasis D001987 7 associated lipids
Bronchial Spasm D001986 18 associated lipids
Bradycardia D001919 13 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Body Weight D001835 333 associated lipids
Bartonella Infections D001474 3 associated lipids
Barrett Esophagus D001471 3 associated lipids
Bacteriuria D001437 7 associated lipids
Bacterial Infections D001424 21 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Arthritis D001168 41 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Angina Pectoris D000787 27 associated lipids
Adenocarcinoma D000230 166 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Achlorhydria D000126 1 associated lipids
Abscess D000038 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Morikawa K et al. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. 1996 Antimicrob. Agents Chemother. pmid:8726002
Arain TM et al. Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. 1996 Antimicrob. Agents Chemother. pmid:8726034
Svensson M et al. Pharmacodynamic effects of nitroimidazoles alone and in combination with clarithromycin on Helicobacter pylori. 2002 Antimicrob. Agents Chemother. pmid:12069981
Giacometti A et al. In vitro activity and killing effect of uperin 3.6 against gram-positive cocci isolated from immunocompromised patients. 2005 Antimicrob. Agents Chemother. pmid:16127075
Peric M et al. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. 2003 Antimicrob. Agents Chemother. pmid:12604536
Comley JC and Sterling AM Effect of atovaquone and atovaquone drug combinations on prophylaxis of Pneumocystis carinii pneumonia in SCID mice. 1995 Antimicrob. Agents Chemother. pmid:7785975
Watanabe K et al. Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice. 2004 Antimicrob. Agents Chemother. pmid:15561829
Struillou L et al. Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. 1995 Antimicrob. Agents Chemother. pmid:7785988
Kim JM et al. Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea. 2004 Antimicrob. Agents Chemother. pmid:15561865
Endo H et al. Effects of lansoprazole and amoxicillin on uptake of [(14)C]clarithromycin into gastric tissue in rats. 2001 Antimicrob. Agents Chemother. pmid:11709323
Taylor DE et al. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. 1997 Antimicrob. Agents Chemother. pmid:9420030
Nash KA and Inderlied CB Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. 1995 Antimicrob. Agents Chemother. pmid:8592991
Alder J et al. Clarithromycin therapy of experimental Treponema pallidum infections in hamsters. 1993 Antimicrob. Agents Chemother. pmid:8494384
Bakker-Woudenberg IA et al. Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination. 2005 Antimicrob. Agents Chemother. pmid:15917538
Traunmüller F et al. Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. 2007 Antimicrob. Agents Chemother. pmid:17606673
Kim YC et al. Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus. 2005 Antimicrob. Agents Chemother. pmid:15917564
Dega H et al. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. 2002 Antimicrob. Agents Chemother. pmid:12234844
Endo H et al. Effects of clarithromycin and amoxicillin on gastric emptying in rats. 2002 Antimicrob. Agents Chemother. pmid:12234874
Yasuda H et al. Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. 1993 Antimicrob. Agents Chemother. pmid:8239580
Kalach N et al. Clarithromycin resistance and eradication of Helicobacter pylori in children. 2001 Antimicrob. Agents Chemother. pmid:11408237
Hammerschlag MR et al. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. 1992 Antimicrob. Agents Chemother. pmid:1324650
Alder J et al. Efficacy of clarithromycin for treatment of experimental Lyme disease in vivo. 1993 Antimicrob. Agents Chemother. pmid:8328782
Mor N and Heifets L Inhibition of intracellular growth of Mycobacterium avium by one pulsed exposure of infected macrophages to clarithromycin. 1993 Antimicrob. Agents Chemother. pmid:8328792
Rastogi N et al. Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. 1991 Antimicrob. Agents Chemother. pmid:1667250
Lazard T et al. Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium. 1993 Antimicrob. Agents Chemother. pmid:8215285
Koh WJ et al. Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. 2015 Antimicrob. Agents Chemother. pmid:25987622
Riska PF et al. Genetic and culture-based approaches for detecting macrolide resistance in Chlamydia pneumoniae. 2004 Antimicrob. Agents Chemother. pmid:15328134
Goldstein EJ et al. Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. 1999 Antimicrob. Agents Chemother. pmid:10543769
Fernández-Roblas R et al. In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials. 2000 Antimicrob. Agents Chemother. pmid:10602744
Khan AA et al. Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis. 1997 Antimicrob. Agents Chemother. pmid:9145840
Collins L and Franzblau SG Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. 1997 Antimicrob. Agents Chemother. pmid:9145860
Kohno Y et al. Autobacteriographic studies of clarithromycin and erythromycin in mice. 1990 Antimicrob. Agents Chemother. pmid:2140497
Lounis N et al. Comparative activities of amikacin against Mycobacterium avium complex in nude and beige mice. 1997 Antimicrob. Agents Chemother. pmid:9145892
Osborne CS et al. In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. 2009 Antimicrob. Agents Chemother. pmid:19596876
Cavalieri SJ et al. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. 1995 Antimicrob. Agents Chemother. pmid:7492101
Hardy DJ et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. 1990 Antimicrob. Agents Chemother. pmid:2143642
Lemaire S et al. Cellular accumulation and pharmacodynamic evaluation of the intracellular activity of CEM-101, a novel fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in human THP-1 macrophages. 2009 Antimicrob. Agents Chemother. pmid:19564365
Subramanian S et al. Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. 2008 Antimicrob. Agents Chemother. pmid:18070962
Steele-Moore L et al. In vitro activities of clarithromycin and azithromycin against clinical isolates of Mycobacterium avium-M. intracellulare. 1999 Antimicrob. Agents Chemother. pmid:10383373
Leuthner KD et al. Pulsatile delivery of clarithromycin alone or in combination with amoxicillin against Streptococcus pneumoniae. 2006 Antimicrob. Agents Chemother. pmid:16436754
García-Arata MI et al. Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin. 1999 Antimicrob. Agents Chemother. pmid:9925537
Hoffner SE et al. Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations. 1993 Antimicrob. Agents Chemother. pmid:8392308
Zhou Z et al. Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China. 2015 Antimicrob. Agents Chemother. pmid:25451048
Gikas A et al. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. 1998 Antimicrob. Agents Chemother. pmid:9756789
Kuo CC et al. In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. 1996 Antimicrob. Agents Chemother. pmid:8913488
Hogan PA and Sheehan DJ Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997. 1998 Antimicrob. Agents Chemother. pmid:9835536
Schuster S et al. Evidence of a Substrate-Discriminating Entrance Channel in the Lower Porter Domain of the Multidrug Resistance Efflux Pump AcrB. 2016 Antimicrob. Agents Chemother. pmid:27161641
Cirioni O et al. Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis. 2008 Antimicrob. Agents Chemother. pmid:18779356
Mor N and Heifets L MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages. 1993 Antimicrob. Agents Chemother. pmid:8431006
Abduljalil K et al. Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. 2009 Antimicrob. Agents Chemother. pmid:19414584
Rouse MS et al. Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis. 1997 Antimicrob. Agents Chemother. pmid:9257739
Cynamon MH et al. Activity of ABT-773 against Mycobacterium avium complex in the beige mouse model. 2000 Antimicrob. Agents Chemother. pmid:10991883
Spaniol V et al. Moraxella catarrhalis AcrAB-OprM efflux pump contributes to antimicrobial resistance and is enhanced during cold shock response. 2015 Antimicrob. Agents Chemother. pmid:25583725
Phillips RO et al. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. 2014 Antimicrob. Agents Chemother. pmid:24323473
Amsden GW et al. Oral cimetidine prolongs clarithromycin absorption. 1998 Antimicrob. Agents Chemother. pmid:9660986
Matic V et al. Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin. 2004 Antimicrob. Agents Chemother. pmid:15504828
Kosowska K et al. Activities of two novel macrolides, GW 773546 and GW 708408, compared with those of telithromycin, erythromycin, azithromycin, and clarithromycin against Haemophilus influenzae. 2004 Antimicrob. Agents Chemother. pmid:15504829
Visalli MA et al. Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin. 1997 Antimicrob. Agents Chemother. pmid:9303375
Spyridaki A et al. Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study. 2012 Antimicrob. Agents Chemother. pmid:22564837
Ednie LM et al. Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004). 1997 Antimicrob. Agents Chemother. pmid:9303406
Seyama S et al. Clarithromycin Resistance Mechanisms of Epidemic β-Lactamase-Nonproducing Ampicillin-Resistant Haemophilus influenzae Strains in Japan. 2016 Antimicrob. Agents Chemother. pmid:26953210
Berry V et al. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. 1998 Antimicrob. Agents Chemother. pmid:9835514
Stone GG et al. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. 1997 Antimicrob. Agents Chemother. pmid:9056021
Furuie H et al. Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. 2010 Antimicrob. Agents Chemother. pmid:19933801
de Lalla F et al. Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. 1992 Antimicrob. Agents Chemother. pmid:1387303
Zhanel GG et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. 2008 Antimicrob. Agents Chemother. pmid:18285482
Ramón-García S et al. Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. 2011 Antimicrob. Agents Chemother. pmid:21576426
Cohen Y et al. Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. 1992 Antimicrob. Agents Chemother. pmid:1332586
Phillips RO et al. Reply to "compliance with antimicrobial therapy for buruli ulcer". 2014 Antimicrob. Agents Chemother. pmid:25225343
Mukherjee D et al. Vancomycin and Clarithromycin Show Synergy against . 2017 Antimicrob. Agents Chemother. pmid:28923867
Tsay FW et al. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. 2017 Antimicrob. Agents Chemother. pmid:28807915
Klemens SP et al. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. 1992 Antimicrob. Agents Chemother. pmid:1336945
Atkinson BA et al. Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin. 1995 Antimicrob. Agents Chemother. pmid:8619588
Bermudez LE et al. Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. 1998 Antimicrob. Agents Chemother. pmid:9449283
Andini N and Nash KA Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. 2006 Antimicrob. Agents Chemother. pmid:16801446
Hsu PI et al. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. 2014 Antimicrob. Agents Chemother. pmid:25070099
van Doorn LJ et al. Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. 2001 Antimicrob. Agents Chemother. pmid:11302817
Cheng KL et al. Effect of grapefruit juice on clarithromycin pharmacokinetics. 1998 Antimicrob. Agents Chemother. pmid:9559810
Piccolomini R et al. In vitro activity of clarithromycin against intracellular Helicobacter pylori. 2001 Antimicrob. Agents Chemother. pmid:11302831
Secka O et al. Antimicrobial susceptibility and resistance patterns among Helicobacter pylori strains from The Gambia, West Africa. 2013 Antimicrob. Agents Chemother. pmid:23263004
Carr RA et al. Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. 1998 Antimicrob. Agents Chemother. pmid:9593146
Brophy DF et al. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. 2000 Antimicrob. Agents Chemother. pmid:10722500
Matsuzaki J et al. Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies. 2012 Antimicrob. Agents Chemother. pmid:22203601
Mougari F et al. Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. 2017 Antimicrob. Agents Chemother. pmid:27799212
Yamaguchi H et al. Chlamydia pneumoniae resists antibiotics in lymphocytes. 2003 Antimicrob. Agents Chemother. pmid:12760877
Ji B et al. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. 1996 Antimicrob. Agents Chemother. pmid:8834886
Jacks SS et al. In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. 2003 Antimicrob. Agents Chemother. pmid:12709351
Goldstein EJ and Citron DM Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents. 1993 Antimicrob. Agents Chemother. pmid:8390810
Giamarellos-Bourboulis EJ et al. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. 2004 Antimicrob. Agents Chemother. pmid:14693524
Hultén K et al. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. 1997 Antimicrob. Agents Chemother. pmid:9371366
Carter G et al. A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation. 2004 Antimicrob. Agents Chemother. pmid:15561879
Hoffman HL et al. Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. 2003 Antimicrob. Agents Chemother. pmid:12543686
Walker KJ et al. Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model. 1994 Antimicrob. Agents Chemother. pmid:7811010
Meyer JM et al. In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. 1997 Antimicrob. Agents Chemother. pmid:9210696
Liu KY et al. Efficacy and pharmacological mechanism of pronase-enhanced low-dose antibiotics for Helicobacter pylori eradication. 2014 Antimicrob. Agents Chemother. pmid:24687504
Chen D et al. Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. 2017 Antimicrob. Agents Chemother. pmid:28167563
Renvoisé A et al. Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex. 2015 Antimicrob. Agents Chemother. pmid:26324275
Obregón-Henao A et al. Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. 2015 Antimicrob. Agents Chemother. pmid:26303795
Nash KA Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38). 2003 Antimicrob. Agents Chemother. pmid:14506008
Best LM et al. Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. 2003 Antimicrob. Agents Chemother. pmid:14506021